MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer
Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer | Clinical Cancer Research
The Role of EGFR-Met Interactions in the Pathogenesis of Glioblastoma and Resistance to Treatment | Bentham Science
Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer | Biomarker Research | Full Text
MET/HGF pathway activation as a paradigm of resistance to targeted therapies - Ko - Annals of Translational Medicine
HER3 and mutant EGFR meet MET | Nature Medicine
Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer? - Cancer Treatment Reviews
Mechanisms of resistance to EGFR tyrosine kinase inhibitors - ScienceDirect
MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib - Nishiyama - 2020 - Cancer Science - Wiley Online Library
Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer? - Cancer Treatment Reviews
Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation - Lung Cancer
Glioblastoma Cell Resistance to EGFR and MET Inhibition Can Be Overcome via Blockade of FGFR-SPRY2 Bypass Signaling - ScienceDirect
Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2 | PNAS
Figure 1 | Mechanisms of Resistance to EGFR TKIs and Development of a New Generation of Drugs in Non-Small-Cell Lung Cancer
PLOS ONE: Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments
![PDF] EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/fb34e0b378ab283ee885fb912c61cc28ae8a288b/3-Figure1-1.png "PDF] EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer | Semantic Scholar")
PDF] EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer | Semantic Scholar
MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition
Crosstalk between the MET and EGFR pathways. HGF: hepatocyte growth... | Download Scientific Diagram
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
Cigarette smoke enhances oncogene addiction to c‐MET and desensitizes EGFR‐expressing non‐small cell lung cancer to EGFR TKIs - Tu - 2018 - Molecular Oncology - Wiley Online Library
Dual inhibition of EGFR and c-Met kinase activation by MJ-56 reduces metastasis of HT29 human colorectal cancer cells
The Crosstalk of c-MET with Related Receptor Tyrosine Kinases in Urothelial Bladder Cancer | IntechOpen
Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors - The Lancet Oncology
